ClinicalTrials.gg

Program

Liraglutide

Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.

Furthest: phase 4, since Jul 22, 2013109 company-led studies, 5 open or runningNext primary completion: Dec 13, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk972 open or runningphase 4since Jul 22, 2013Sep 8, 2005Dec 13, 2026phase 1 · NCT07225816
4Moving Biotech20 open or runningphase 2since Sep 24, 2025Jun 7, 2022none ahead
Eli Lilly20 open or runningphase 4since Feb 24, 2014May 31, 2013none ahead
Tonghua Dongbao Pharmaceutical22 open or runningphase 3since Aug 14, 2024Jun 2, 2024none ahead
Biolingus11 open or runningphase 2since Feb 16, 2022Feb 16, 2022none ahead
Cinnagen10 open or runningphase 3since Jan 29, 2018Jan 29, 2018none ahead
ikfe-cro-gmbh10 open or runningphase 4since Sep 17, 2010Sep 17, 2010none ahead
Merck10 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Pfizer10 open or runningphase 1since Feb 1, 2017Feb 1, 2017none ahead
Sino Biopharmaceutical10 open or runningphase 1since Aug 24, 2021Aug 24, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Jan 16, 2012.

  1. Sep 20, 20162 phase 3 studiesNovo Nordisk · NCT02911948, NCT02918279
  2. Nov 10, 20163 phase 3 studiesNovo Nordisk · NCT02963935, NCT02963922, NCT02964247
  3. Feb 1, 2017Pfizer's first study: phase 1 study in ObesityNew to PfizerPfizer · NCT03041792 · 61 enrolled · United States
  4. May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
  5. Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
  6. Jan 29, 2018Cinnagen's first study: phase 3 study in Diabetes Mellitus, Type 2New to CinnagenCinnagen · NCT03421119 · 300 enrolled
  7. Feb 26, 2021Phase 3 study in ObesityNovo Nordisk · NCT04775082 · 82 enrolled · United States, Belgium, India and more
  8. Aug 24, 2021Sino Biopharmaceutical's first study: phase 1 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05029076 · 28 enrolled · China
  9. Feb 16, 2022Biolingus's first study: phase 2 study in Diabetes Mellitus, Type 2New to BiolingusBiolingus · NCT05268237 · 15 planned · Hong Kong
  10. Jun 7, 20224Moving Biotech's first study: phase 1 study in Osteoarthritis, KneeNew to 4Moving Biotech4Moving Biotech · NCT05419856 · 34 enrolled · Belgium
  11. Jun 2, 2024Tonghua Dongbao Pharmaceutical's first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
  12. Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
  13. Sep 24, 2025Phase 2 study in Osteoarthritis, Knee4Moving Biotech · NCT07225829 · 130 enrolled · United States, Canada, Denmark and more
  14. Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States

Ahead

  1. Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

The newest 60 of 109 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07225816Obesity · United States1RecruitingNovo NordiskDec 13, 202671
NCT07225829Osteoarthritis, Knee · United States, Canada, Denmark and more2Completed4Moving BiotechAug 31, 2026130
NCT06559722Diabetes Mellitus, Type 23Not yet recruitingTonghua Dongbao PharmaceuticalOct 2025510
NCT06449703Healthy · China1RecruitingTonghua Dongbao PharmaceuticalJun 16, 202444
NCT05419856Osteoarthritis, Knee · Belgium1Completed4Moving BiotechOct 31, 202334
NCT05268237Diabetes Mellitus, Type 2 · Hong Kong2RecruitingBiolingusDec 202515
NCT05029076Diabetes Mellitus, Type 2 · China1CompletedSino BiopharmaceuticalJun 1, 201928
NCT04775082Obesity · United States, Belgium, India and more3Active, not recruitingNovo NordiskAug 1, 202382
NCT03421119Diabetes Mellitus, Type 23UNKNOWNCinnagenDec 1, 2019300
NCT03292185Diabetes Mellitus · China1CompletedNovo NordiskJan 2, 201824
NCT03175120Diabetes Mellitus · China, Hong Kong3CompletedNovo NordiskMar 5, 2019453
NCT03172494Diabetes Mellitus · China3CompletedNovo NordiskJun 14, 2019720
NCT03041792Obesity · United States1CompletedPfizerJan 16, 201861
NCT02964247Diabetes Mellitus · United States, Brazil, India and more3CompletedNovo NordiskMay 4, 2018303
NCT02963935Nutrition Disorders · United States3CompletedNovo NordiskMay 23, 2018282
NCT02963922Nutrition Disorders · United States, Canada, Germany and more3CompletedNovo NordiskSep 10, 2018396
NCT02918279Nutrition Disorders · United States, Belgium, Mexico and more3CompletedNovo NordiskFeb 14, 2019251
NCT02911948Diabetes Mellitus · Japan3CompletedNovo NordiskNov 17, 2017210
NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more3CompletedNovo NordiskSep 26, 2017420
NCT02730377Diabetes Mellitus · United States, Canada, Colombia and more4CompletedNovo NordiskAug 5, 20191,991
NCT02717858Nutrition Disorders · Denmark1CompletedNovo NordiskFeb 27, 201752
NCT02696148Nutrition Disorders · United States1CompletedNovo NordiskApr 13, 201724
NCT02607306Diabetes Mellitus · Japan3CompletedNovo NordiskDec 15, 2017819
NCT02527200Nutrition Disorders · United States, Australia, Canada and more3CompletedNovo NordiskNov 4, 202056
NCT02505334Diabetes Mellitus · Japan3CompletedNovo NordiskMay 2, 2017635
NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more3CompletedNovo NordiskOct 3, 20181,012
NCT02443155Diabetes Mellitus · United States, Austria, Belgium and more2CompletedNovo NordiskAug 31, 2018308
NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more3CompletedNovo NordiskOct 5, 2016506
NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more3CompletedNovo NordiskDec 23, 2015420
NCT02207348Nutrition Disorders · Germany1CompletedNovo NordiskSep 201424
NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNovo NordiskApr 201531
NCT02098395Diabetes Mellitus · United States, Austria, Belgium and more3CompletedNovo NordiskApr 2015835
NCT02072096Diabetes Mellitus, Type 2 · United States, Austria, Germany and more4TerminatedEli LillyOct 2015192
NCT02008682Diabetes Mellitus · China4CompletedNovo NordiskNov 2014368
NCT01973231Diabetes Mellitus · Czech Republic, Finland, France and more4CompletedNovo NordiskNov 2014404
NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNovo NordiskNov 4, 2014557
NCT01916174Diabetes Mellitus · Germany1CompletedNovo NordiskNov 201350
NCT01917656Diabetes Mellitus · Algeria, India, Israel and more4CompletedNovo NordiskSep 1, 2014343
NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more4CompletedNovo NordiskJun 15, 2015407
NCT01870297Diabetes Mellitus, Type 2 · United States1CompletedEli LillyDec 201472
NCT01836523Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNovo NordiskJun 20151,398
NCT01789086Nutrition Disorders · Germany1CompletedNovo NordiskMay 201421
NCT01620489Diabetes Mellitus · United States, France, Poland and more3CompletedNovo NordiskAug 20, 2013279
NCT01620476Diabetes Mellitus · Japan1CompletedNovo NordiskMar 200424
NCT01620463Diabetes Mellitus · Japan1CompletedNovo NordiskMar 200332
NCT01617434Diabetes Mellitus · United States, Argentina, Canada and more3CompletedNovo NordiskOct 2013451
NCT01615978Diabetes Mellitus · Japan1CompletedNovo NordiskMar 200415
NCT01572740Diabetes Mellitus · Japan3CompletedNovo NordiskNov 1, 2012257
NCT01557166Nutrition Disorders · United States, Canada3CompletedNovo NordiskJun 1, 2013359
NCT01541215Diabetes Mellitus · United States, Australia, Austria and more3CompletedNovo NordiskNov 15, 2017135
NCT01536665Diabetes Mellitus · Austria1CompletedNovo NordiskAug 201245
NCT01517568Diabetes Mellitus · Netherlands1CompletedNovo NordiskDec 20067
NCT01517555Diabetes Mellitus · Germany1CompletedNovo NordiskMay 200718
NCT01516255Diabetes Mellitus · United States1CompletedNovo NordiskNov 200664
NCT01515592Diabetes Mellitus · Japan1CompletedNovo NordiskApr 200624
NCT01515579Diabetes Mellitus · Sweden1CompletedNovo NordiskJun 200622
NCT01515553Diabetes Mellitus · Sweden1CompletedNovo NordiskApr 200722
NCT01518166Diabetes Mellitus · Sweden1CompletedNovo NordiskApr 200770
NCT01514487Diabetes Mellitus · Australia1CompletedNovo NordiskMar 30, 200524
NCT01513525Diabetes Mellitus · Germany1CompletedNovo NordiskMay 200721

How it is read

Names in the registry

  • “liraglutide”, 114 entries
  • “insulin degludec/liraglutide”, 11 entries
  • “Liraglutide”, 10 entries
  • “Insulin degludec/liraglutide”, 3 entries
  • “NN9924 (oral)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.